Kedrion Biopharma
Dragica Strizel is an experienced technology professional with a strong background in systems architecture, analysis, and quality assurance. Currently serving as a Senior Solutions Architect at Kedrion Biopharma since October 2017, Dragica focuses on designing and implementing solutions that enhance efficiency and minimize errors. Previous roles include Senior Analyst at BPL Plasma and Senior Programmer Analyst at Blood Systems Inc, where Dragica evaluated and troubleshot blood banking systems while also contributing to project management and business intelligence efforts. Additional experience includes consulting on quality assurance for medical devices and managing the development of an Order Entry System. Dragica holds a Bachelor of Science degree in Computer Science from St. Cyril and Methodius University Skopje.
This person is not in any offices
Kedrion Biopharma
19 followers
Kedrion Biopharma is a biopharmaceutical company that collects and fractionates blood plasma to produce and distribute worldwide plasma-derived therapies for use in treating and preventing rare and serious diseases and conditions. In 2022, Kedrion joined forces with BPL (Bio Products Laboratory). Based in the United Kingdom, BPL has over 60 years of experience in the supply of high-quality plasma-derived medicines to treat rare diseases. Kedrion distributes its products in over 100 countries around the world. We have plants in Italy, Hungary, UK and North America, and plasma collection centers in the US and in the Czech Republic. With these figures we are the world’s 5th top player in the field of plasma-derived products. Our goal is to build a diverse and professional workforce, providing job opportunities for talented external candidates as well as internal employees who aim to grow with us. Because our work includes so many interests and skills – from Research to Sales; Plasma Collection to Production – there are abundant possibilities for learning and growth. Kedrion builds bridges: from donors to patients, from plasma to therapies, from challenge to hope.